CN103275189A - 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用 - Google Patents
一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用 Download PDFInfo
- Publication number
- CN103275189A CN103275189A CN2013102224657A CN201310222465A CN103275189A CN 103275189 A CN103275189 A CN 103275189A CN 2013102224657 A CN2013102224657 A CN 2013102224657A CN 201310222465 A CN201310222465 A CN 201310222465A CN 103275189 A CN103275189 A CN 103275189A
- Authority
- CN
- China
- Prior art keywords
- tfa
- somatostatin
- resin
- edt
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 90
- 239000011347 resin Substances 0.000 title claims abstract description 77
- 229920005989 resin Polymers 0.000 title claims abstract description 77
- 108010056088 Somatostatin Proteins 0.000 title claims abstract description 43
- 102000005157 Somatostatin Human genes 0.000 title claims abstract description 39
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title claims abstract description 39
- 229960000553 somatostatin Drugs 0.000 title claims abstract description 39
- 238000005336 cracking Methods 0.000 title abstract description 27
- 230000002194 synthesizing effect Effects 0.000 title abstract description 3
- 239000007788 liquid Substances 0.000 title abstract 7
- 239000007790 solid phase Substances 0.000 title description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 96
- 238000006243 chemical reaction Methods 0.000 claims abstract description 48
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000006166 lysate Substances 0.000 claims description 50
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 5
- 238000010504 bond cleavage reaction Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- 239000000706 filtrate Substances 0.000 description 36
- 238000005406 washing Methods 0.000 description 27
- 238000001291 vacuum drying Methods 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 12
- 230000001590 oxidative effect Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 2
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003746 solid phase reaction Methods 0.000 description 2
- 238000010671 solid-state reaction Methods 0.000 description 2
- -1 somatostatin Chemical compound 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 230000003488 thyrotrophic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
英文缩写 | 中文含义 |
Fmoc | 9-芴甲氧羰基 |
Boc | 叔丁氧羰基 |
tBu | 叔丁基 |
Trt | 三苯甲基 |
DMF | N,N-二甲基甲酰胺 |
DCM | 二氯甲烷 |
DIC | N,N-二异丙基碳二亚胺 |
DIPEA | N,N-二异丙基乙胺 |
HOBT | 1-羟基苯并三唑 |
TFE | 三氟乙醇 |
TFA | 三氟乙酸 |
EDT | 1,2-乙二硫醇 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310222465.7A CN103275189B (zh) | 2013-06-06 | 2013-06-06 | 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310222465.7A CN103275189B (zh) | 2013-06-06 | 2013-06-06 | 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103275189A true CN103275189A (zh) | 2013-09-04 |
CN103275189B CN103275189B (zh) | 2014-08-06 |
Family
ID=49057830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310222465.7A Active CN103275189B (zh) | 2013-06-06 | 2013-06-06 | 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103275189B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104311639A (zh) * | 2014-10-10 | 2015-01-28 | 海南中和药业有限公司 | 一种生长抑素的合成工艺 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127259A (zh) * | 1994-09-06 | 1996-07-24 | 山道士有限公司 | 肽类 |
CN1508152A (zh) * | 2002-12-17 | 2004-06-30 | 常州市第四制药厂有限公司 | 生长抑素全合成新方法 |
CN1552728A (zh) * | 2003-05-29 | 2004-12-08 | 上海子能药物研究有限公司 | 一种生长抑素的合成方法 |
CN1739789A (zh) * | 2005-05-11 | 2006-03-01 | 北京双鹭药业股份有限公司 | 一种生长抑素的水溶液制剂、其制备方法及应用 |
CN1923851A (zh) * | 2005-08-30 | 2007-03-07 | 上海子能制药有限公司 | 固相多肽合成生长抑素的制备方法 |
CN101508724A (zh) * | 2009-04-09 | 2009-08-19 | 吴永平 | 十四肽生长抑素的制备方法 |
CN101570570A (zh) * | 2009-06-03 | 2009-11-04 | 兰州大学 | 一种生长抑素的合成方法 |
CN102268073A (zh) * | 2011-07-19 | 2011-12-07 | 南昌佰泰生物科技有限公司 | 一种制备生长抑素的方法 |
CN102382188A (zh) * | 2011-11-07 | 2012-03-21 | 深圳翰宇药业股份有限公司 | 醋酸卡培立肽的制备方法 |
CN102952175A (zh) * | 2011-08-19 | 2013-03-06 | 上海苏豪逸明制药有限公司 | 固相多肽合成生长抑素的方法 |
-
2013
- 2013-06-06 CN CN201310222465.7A patent/CN103275189B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127259A (zh) * | 1994-09-06 | 1996-07-24 | 山道士有限公司 | 肽类 |
CN1508152A (zh) * | 2002-12-17 | 2004-06-30 | 常州市第四制药厂有限公司 | 生长抑素全合成新方法 |
CN1552728A (zh) * | 2003-05-29 | 2004-12-08 | 上海子能药物研究有限公司 | 一种生长抑素的合成方法 |
CN1739789A (zh) * | 2005-05-11 | 2006-03-01 | 北京双鹭药业股份有限公司 | 一种生长抑素的水溶液制剂、其制备方法及应用 |
CN1923851A (zh) * | 2005-08-30 | 2007-03-07 | 上海子能制药有限公司 | 固相多肽合成生长抑素的制备方法 |
CN101508724A (zh) * | 2009-04-09 | 2009-08-19 | 吴永平 | 十四肽生长抑素的制备方法 |
CN101570570A (zh) * | 2009-06-03 | 2009-11-04 | 兰州大学 | 一种生长抑素的合成方法 |
CN102268073A (zh) * | 2011-07-19 | 2011-12-07 | 南昌佰泰生物科技有限公司 | 一种制备生长抑素的方法 |
CN102952175A (zh) * | 2011-08-19 | 2013-03-06 | 上海苏豪逸明制药有限公司 | 固相多肽合成生长抑素的方法 |
CN102382188A (zh) * | 2011-11-07 | 2012-03-21 | 深圳翰宇药业股份有限公司 | 醋酸卡培立肽的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104311639A (zh) * | 2014-10-10 | 2015-01-28 | 海南中和药业有限公司 | 一种生长抑素的合成工艺 |
CN104311639B (zh) * | 2014-10-10 | 2018-02-23 | 海南中和药业股份有限公司 | 一种生长抑素的合成工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN103275189B (zh) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3398960B1 (en) | Method for preparing semaglutide | |
CN102875655B (zh) | 一种合成利那洛肽的方法 | |
US20130289241A1 (en) | Method for preparing exenatide | |
CN102702320B (zh) | 一种制备爱啡肽的方法 | |
CN103304659B (zh) | 利拉鲁肽的固相制备方法 | |
CN103497245A (zh) | 一种合成胸腺法新的方法 | |
CN103145827A (zh) | 一种乌拉力肽的固相合成方法 | |
EP3398957A1 (en) | Method for synthesizing etelcalcetide | |
CN101747426A (zh) | 一种合成普兰林肽的方法 | |
CN106554391B (zh) | 一种海洋生物肽Xen2174的合成方法 | |
CN117106055A (zh) | 一种替尔泊肽的合成方法 | |
CN107383170A (zh) | 一种普卡那肽的简易合成方法 | |
CN115651075B (zh) | 一种Tirzepatide的合成方法 | |
CN109021087A (zh) | 一种固液相结合制备齐考诺肽的方法 | |
CN103275189B (zh) | 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用 | |
CN112574285B (zh) | 一种含一对二硫键的多肽药物的固液相合成方法 | |
CN112979759A (zh) | 一种固液结合制备普卡那肽的方法 | |
CN108047324A (zh) | 一种ω-芋螺毒素GVIA的制备方法 | |
CN118005767A (zh) | 一种固液结合制备Tirzepatide的方法 | |
WO2020248360A1 (zh) | 一种维拉卡肽的合成方法 | |
CN115746099A (zh) | 一种通过二次环化固相合成普卡那肽的方法 | |
CN113549145B (zh) | 一种生长抑素的制备方法 | |
CN111393508B (zh) | 一种阿托西班的制备方法 | |
CN108676086A (zh) | 一种利拉鲁肽的合成方法 | |
CN111233980B (zh) | 一种戈舍瑞林的片段法合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Cracking liquid for peptide resin, and application thereof in synthesizing somatostatin by solid phase cracking Effective date of registration: 20200313 Granted publication date: 20140806 Pledgee: Shenzhen hi tech investment small loan Co., Ltd Pledgor: HYBIO PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980000692 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220513 Granted publication date: 20140806 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: HYBIO PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980000692 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |